HCT116 Cells

HCT116 cells, isolated from a colon cancer patient, serve a crucial role in therapeutic studies and drug screenings, particularly in colon cancer research. HCT-116 cells are recognized for a mutation in codon 13 of the KRAS proto-oncogene, highlighting their utility in gene therapy research, especially since they are amenable to transfection with viral vectors. In apoptosis research, HCT116 cells are pivotal for studying the mechanisms of apoptosis and cell death. The effects of butyrate, a short-chain fatty acid, have been extensively studied in HCT116 cells, revealing that butyrate inhibits colon cancer proliferation by inducing apoptosis, highlighting the intricate cancer-cell interaction and the broader implications for cancer research. Butyrate's role in modulating gene expression changes and inducing endoplasmic reticulum stress response in HCT116 cells underscores the cellular complexity in colorectal cancer cell lines. The interaction between HCT116 colon cancer cells and therapeutic agents like metformin, known for its legacy effect and potential to reduce the risk of cancer, is of significant interest. Metformin's influence on HCT116 colon cell proliferation, p21 protein level modulation, and its broader implications on proliferation and growth offer insights into the management of primary tumors and the prevention of tumors and metastases. HCT116 cells are invaluable for oncological research, providing critical insights into the efficacy of therapeutics and the molecular dynamics of cancer progression. With a notable KRAS mutation and susceptibility to transfection, these cells facilitate gene therapy studies, apoptosis analysis, and colorectal cancer treatment and prevention strategies. Intestine cancer cell lines, Colorectal, Adenocarcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1